Immunotherapy treatment offers hope for men with hard-to-treat prostate cancer

10 July 2023

Research coordinated by the CR UK & UCL CTC is showing promising signs for men with a certain type of prostate cancer.

Prostate cancer remains the most common type of cancer among men in the UK, with over 50,000 cases diagnosed each year. Because the disease requires the hormone testosterone in order to grow, some of these men have either hormone therapy or their testicles removed as part of treatment. Whilst this can initially keep their cancer from returning, it often becomes ineffective over time.

The NEPTUNES trial has been treating a number of patients whose cancer has returned after this treatment with a pair of immunotherapy drugs called nivolumab and ipilimumab. These stimulate the body's immune system to fight the cancer, with a third of patients on the trial having a positive response.

Speaking to The Daily Mail, the study's Chief Investigator Dr Mark Linch explained why this is promising: "I recently received an email from a woman whose husband had been told by doctors there was no further treatment for his prostate cancer and they were struggling to control his symptoms. He is now doing really well after having the [immunotherapy] treatment as part of a trial"

The full article, which summarises recent innovations in prostate cancer screening and treatment in the UK, can be read here.

Image shows University College Hospital building, part of UCLH, one of the sites where the Neptunes trial took place.

Credit: Mary Hinkley

More news articles

'Bridging the Gap': CTC organises collaborative event to raise awareness of clinical trials

Esther Arthur-Darkwa, trial manager at the Cancer Trials Centre, reports back from this weekend's event in Nottingham: In 2022 the UCL CTC e [...]

Results of cervical cancer trial hailed as 'biggest breakthrough for decades'

Findings from a CTC-led study into cervical cancer treatment have been published in the Lancet today, prompting further coverage for a trial [...]

Launch of the international SAFIR ABC10 program for patients with biliary tract cancer

Unicancer, University College of London (UCL) and the Belgian Group of Digestive Oncology (BGDO) announce the launch of the flagship SAFIR A [...]

Gynaecological Cancer Awareness Month in the UK

September marks Gynaecological Cancer Awareness Month in the UK, an annual campaign established by the Foundation for Women's Cancer (FWC) i [...]

Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map

Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899

CTC staff

University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000